Switching to Long-Acting Cabotegravir Plus Rilpirivine for HIV Treatment: Assessing Candidacy and Patient Counseling

In this episode,  an international expert panel shares their thoughts on key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, including selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience. Subsequent episodes in this 4-part series will cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including operational planning, clinic impact, and handling missed doses with long-acting antiretroviral therapy for treatment; long-acting HIV pre-exposure prophylaxis; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.Presenters:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisYvonne Gilleece, MB, BCh, BAOHonorary Clinical Professor in HIV Medicine and Sexual HealthDepartment of Global Health & HIVBrighton & Sussex Medical SchoolConsultant in HIV Medicine and Sexual HealthHIV DepartmentUniversity Hospitals Sussex NHS Foundation TrustBrighton, United Kingdom Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyDarrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program:https://bit.ly/3P3uPBc Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.